Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (269)
Related Products (269)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
ABBV-992
0 ImagesCat. No.: HY-163827CAS No.: 2792171-84-5
-
PROTAC BTK/IKZF1/3 Degrader-1
0 ImagesCat. No.: HY-179077CAS No.: 2416130-49-7PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma. (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179076); Blue: CRBN ligand (HY-41547))
-
Pirtobrutinib-13C,d3
0 ImagesCat. No.: HY-131328SSynonyms: LOXO-305-13C,d3Pirtobrutinib-13C,d3 (LOXO-305-13C,d3) is the deuterated, 13C-labeled Pirtobrutinib (HY-131328). Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
-
PROTAC BTK Degrader-4
0 ImagesCat. No.: HY-128408CAS No.: 2893795-12-3PROTAC BTK Degrader-4 (compound 15) is a potent PROTAC Bruton's tyrosine kinases (BTK) degrader (DC50 < 100 nM) with little immunomodulatory imide drug (IMiD) activity (DC50 = 0.345 μM, Dmax = 27.4%). PROTAC BTK Degrader-4 can be used for cancers, autoimmune diseases, and inflammatory diseases that are mediated by BTK.
-
Avitinib maleate dihydrate
0 ImagesCat. No.: HY-168427CAS No.: 1822357-78-7Synonyms: Abivertinib maleate dihydrate; AC0010 maleate dihydrateAvitinib (Abivertinib) maleate dihydrate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate dihydrate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate dihydrate shows anticancer effects.
-
(R)-Acalabrutinib
0 ImagesCat. No.: HY-W062695CAS No.: 1952316-43-6Synonyms: (R)-ACP-196(R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK).
-
CTA056
0 ImagesCat. No.: HY-110113CAS No.: 1265822-30-7
-
BTK-IN-37
0 ImagesCat. No.: HY-159589BTK-IN-37 (compound 8d) is a BTK inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with Ki and IC50 of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis.
-
(R)-Zanubrutinib-d5
0 ImagesCat. No.: HY-101474BS(R)-Zanubrutinib-d5 is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
-
BTK-IN-19
0 ImagesCat. No.: HY-152212CAS No.: 1374240-01-3BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM.
-
PROTAC BTK Degrader-3
0 ImagesCat. No.: HY-153536CAS No.: 2563861-90-3
-
BTK C481R Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70808Bruton's tyrosine kinase (BTK) plays a vital role in B-cell antigen receptor (BCR) signalling transduction pathway. BTK can be used for the study of lymphomas and autoimmune diseases. BTK has multiple mutants. BTK C481R Recombinant Human Active Protein Kinase is a recombinant BTK C481R protein that can be used to study BTK C481R-related functions.
-
BTK-IN-3
0 ImagesCat. No.: HY-141689CAS No.: 1226872-27-0
-
PROTAC BTK Degrader-9
0 ImagesCat. No.: HY-162280CAS No.: 3034024-77-3PROTAC BTK Degrader-9 is a potent BTK PROTAC degrader with a DC50 of 1.29 nM (in Mino cells at 4 h). PROTAC BTK Degrader-9 induces the formation of a stable ternary complex with BTK and the CRBN E3 ubiquitin ligase, thereby mediating proteasomal degradation of BTK in a CRBN-dependent manner. PROTAC BTK Degrader-9 downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. PROTAC BTK Degrader-9 alleviates alveolar bone resorption in periodontitis models of Mus musculus (house mouse). PROTAC BTK Degrader-9 can be used in research related to periodontitis.
